{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:40:40Z","timestamp":1720078840868},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"DOI":"10.7759\/cureus.63791","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T06:55:36Z","timestamp":1720076136000},"source":"Crossref","is-referenced-by-count":0,"title":["Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Maria","family":"Loutsou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki E","family":"Georgakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Roussakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Chadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paschalis","family":"Steiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234785","article-title":"The impact of the COVID-19 pandemic on the global tuberculosis epidemic","volume":"14","author":"Falzon D","year":"2023","unstructured":"Falzon D, Zignol M, Bastard M, Floyd K, Kasaeva T. The impact of the COVID-19 pandemic on the global tuberculosis epidemic. Front Immunol. 2023, 14:1234785. 10.3389\/fimmu.2023.1234785","journal-title":"Front Immunol"},{"key":"ref2","unstructured":"Incidence of tuberculosis (per 100,000 people). (2024). Accessed. June 18, 2024: https:\/\/data.worldbank.org\/indicator\/SH.TBS.INCD."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin C","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, et al.. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020, 71:762-8. 10.1093\/cid\/ciaa248","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2016.03.003","article-title":"Miliary tuberculosis: a new look at an old foe","volume":"3","author":"Sharma SK","year":"2016","unstructured":"Sharma SK, Mohan A, Sharma A. Miliary tuberculosis: a new look at an old foe. J Clin Tuberc Other Mycobact Dis. 2016, 3:13-27. 10.1016\/j.jctube.2016.03.003","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli EM","year":"2019","unstructured":"Elli EM, Barat\u00e8 C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019, 9:1186. 10.3389\/fonc.2019.01186","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2389038","article-title":"Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib","volume":"2016","author":"Abidi MZ","year":"2016","unstructured":"Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016, 2016:2389038. 10.1155\/2016\/2389038","journal-title":"Case Rep Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4994","article-title":"WHO report: years of progress in global tuberculosis upset by COVID-19 pandemic","volume":"3","author":"Stephenson J","year":"2022","unstructured":"Stephenson J. WHO report: years of progress in global tuberculosis upset by COVID-19 pandemic. JAMA Health Forum. 2022, 3:e224994. 10.1001\/jamahealthforum.2022.4994","journal-title":"JAMA Health Forum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/828939","article-title":"Risk factors for tuberculosis","volume":"2013","author":"Narasimhan P","year":"2013","unstructured":"Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013, 2013:828939. 10.1155\/2013\/828939","journal-title":"Pulm Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.054","article-title":"Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19","volume":"81","author":"Liu Z","year":"2020","unstructured":"Liu Z, Long W, Tu M, et al.. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect. 2020, 81:318-56. 10.1016\/j.jinf.2020.03.054","journal-title":"J Infect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3201\/eid2611.202752","article-title":"Four patients with COVID-19 and tuberculosis, Singapore, April-May 2020","volume":"26","author":"Tham SM","year":"2020","unstructured":"Tham SM, Lim WY, Lee CK, et al.. Four patients with COVID-19 and tuberculosis, Singapore, April-May 2020. Emerg Infect Dis. 2020, 26:2764-6. 10.3201\/eid2611.202752","journal-title":"Emerg Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19316","article-title":"Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma","volume":"115","author":"Kampmann B","year":"2005","unstructured":"Kampmann B, Hemingway C, Stephens A, et al.. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest. 2005, 115:2480-8. 10.1172\/JCI19316","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S23277","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"8","author":"Ostojic A","year":"2012","unstructured":"Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012, 8:95-103. 10.2147\/TCRM.S23277","journal-title":"Ther Clin Risk Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba C","year":"2012","unstructured":"Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, Tolomeo M. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012, 5:552. 10.1186\/1756-0500-5-552","journal-title":"BMC Res Notes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1045869","article-title":"Ruxolitinib for the treatment of patients with polycythemia vera","volume":"8","author":"Kiladjian JJ","year":"2015","unstructured":"Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015, 8:391-401. 10.1586\/17474086.2015.1045869","journal-title":"Expert Rev Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.02.003","article-title":"Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: case series and literature review","volume":"14","author":"Khalid F","year":"2021","unstructured":"Khalid F, Damlaj M, AlZahrani M, Abuelgasim KA, Gmati GE. Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: case series and literature review. Hematol Oncol Stem Cell Ther. 2021, 14:252-6. 10.1016\/j.hemonc.2020.02.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.104","article-title":"Disseminated tuberculosis associated with ruxolitinib","volume":"28","author":"Hopman RK","year":"2014","unstructured":"Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014, 28:1750-1. 10.1038\/leu.2014.104","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2684-0","article-title":"Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib","volume":"95","author":"Branco B","year":"2016","unstructured":"Branco B, Metsu D, Dutertre M, Marchou B, Delobel P, Recher C, Martin-Blondel G. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016, 95:1207-9. 10.1007\/s00277-016-2684-0","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen YH","year":"2015","unstructured":"Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015, 56:1528-9. 10.3109\/10428194.2014.963082","journal-title":"Leuk Lymphoma"},{"key":"ref19","article-title":"[Fatal tuberculosis during treatment with ruxolitinib]","volume":"159","author":"Keizer S","year":"2015","unstructured":"Keizer S, Gerritsen R, Jauw Y, Janssen J, Koopman B, Bresser P. [Fatal tuberculosis during treatment with ruxolitinib]. Ned Tijdschr Geneeskd. 2015, 159:A8650.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri F","year":"2015","unstructured":"Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015, 94:519-20. 10.1007\/s00277-014-2183-0","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/270433-miliary-tb-and-covid-19-coinfection-in-a-patient-with-a-history-of-post-polycythemia-vera-myelofibrosis-treated-with-ruxolitinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T06:55:42Z","timestamp":1720076142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/270433-miliary-tb-and-covid-19-coinfection-in-a-patient-with-a-history-of-post-polycythemia-vera-myelofibrosis-treated-with-ruxolitinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.63791","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}